Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The Principal Investigator believes that Vitamin E δ-Tocotrienol will slow the progression of
pancreatic cancer cells. Therefore, the investigators must determine the safety and
tolerability of Vitamin E δ-Tocotrienol in healthy participants before administering to
cancer patients. The investigators will do this by giving participants a dose of up to1600 mg
twice a day, not to exceed 3200 mg total for 14 consecutive days.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
BioGene Life Science National Cancer Institute (NCI)
Treatments:
alpha-Tocopherol Tocopherols Tocotrienols Vitamin E Vitamins